Oncology
18 drugs are in development for Head and Neck Cancer.
- Companies
- 7
- Clinical trials
- 73
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Head and Neck Cancer pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 2(6)
Phase 1(12)
| Drug | Company |
|---|---|
| [225ac]ac-aky-1189 | Aktis Oncology Inc. (AKTS) |
| ALX2004 | ALX ONCOLOGY HOLDINGS INC (ALXO) |
| CTX-471 | Compass Therapeutics, Inc. (CMPX) |
| CUE-101 | Cue Biopharma, Inc. (CUE) |
| tsc-200-a0201 | TScan Therapeutics, Inc. (TCRX) |
| tsc-201-b0702 | TScan Therapeutics, Inc. (TCRX) |
| tsc-202-a0201 | TScan Therapeutics, Inc. (TCRX) |
| tsc-203-a0201 | TScan Therapeutics, Inc. (TCRX) |
| tsc-204-a0101 | TScan Therapeutics, Inc. (TCRX) |
| tsc-204-a0201 | TScan Therapeutics, Inc. (TCRX) |
| tsc-204-c0702 | TScan Therapeutics, Inc. (TCRX) |
| uza-cel | Adaptimmune Therapeutics PLC (ADAP) |
About this indication
Head and Neck Cancer context
Oncology·MeSH: Head and Neck Neoplasms (D006258)
Narrower concept of MeSH descriptor Head and Neck Neoplasms
Prevalence
14.0 / 100K
Incidence
6.0 / 100K/yr
Compare drugs
Frequently asked questions
How many drugs are in development for Head and Neck Cancer?
BioSniper tracks 18 drugs in development for Head and Neck Cancer across 7 companies.
How many clinical trials target Head and Neck Cancer?
There are 73 clinical trials targeting Head and Neck Cancer tracked by BioSniper.
What is the prevalence of Head and Neck Cancer?
The estimated prevalence of Head and Neck Cancer is approximately 14.0 per 100,000 population.